Related Experiment Video
Updated: Mar 28, 2026

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
Published on: November 7, 2018
Clinical relevance of the study of hepatitis B virus covalently closed circular DNA
Rajneesh Kumar1,2, Sofía Pérez-Del-Pulgar1,3, Barbara Testoni1,2
1Cancer Research Center of Lyon (CRCL), INSERM U1052, CNRS 5286, Lyon, France.
Insights
Hepatitis B virus (HBV) infection affects millions globally. Current treatments cannot eliminate the persistent cccDNA, a viral DNA form crucial for replication and disease progression, highlighting the need for new therapies.
Area of Science:
- Hepatology
- Virology
- Molecular Biology
Background:
- Hepatitis B virus (HBV) infection is a significant global health issue, impacting 240 million individuals worldwide.
- HBV replicates its genome within hepatocytes, a process involving the formation of nuclear covalently closed circular DNA (cccDNA).
- This cccDNA acts as a viral mini-chromosome, essential for sustained viral replication and infection persistence.
Purpose of the Study:
- To highlight the critical role of covalently closed circular DNA (cccDNA) in persistent Hepatitis B virus (HBV) infection.
- To underscore the limitations of current antiviral therapies in eradicating cccDNA.
- To emphasize the necessity of developing novel strategies targeting cccDNA for a potential HBV cure.
Main Methods:
- Literature review and synthesis of current knowledge on HBV replication and cccDNA.
- Analysis of the clinical implications of persistent cccDNA, including reactivation, recurrence, and hepatocellular carcinoma (HCC).
- Identification of cccDNA as the primary target for new antiviral drug development.
Main Results:
- cccDNA persists in infected hepatocytes, even when HBV DNA and HBsAg are undetectable in serum.
- Persistent cccDNA is linked to adverse clinical outcomes such as viral reactivation, post-transplant recurrence, and HCC development.
- Current antiviral drugs are ineffective against cccDNA, which cannot be directly measured in serum.
Conclusions:
- cccDNA is the main obstacle to achieving a cure for Hepatitis B virus infection.
- Novel antiviral strategies aimed at degrading or silencing cccDNA are urgently needed.
- Further research into cccDNA biology and targeting is essential for advancing HBV treatment.
Abstract:
Hepatitis B virus (HBV) remains a public health concern with 240 million people affected worldwide. HBV is an hepadnavirus that replicates its genome in hepatocytes. One of the key steps of the viral life cycle is the formation of cccDNA - covalently closed circular DNA - in the nucleus, the equivalent of a viral mini-chromosome that acts as a template for subsequent virus replication. Current antiviral medications are not effective in eradicating cccDNA, which can persist in the infected liver even in the absence of detectable HBV DNA or HBsAg in the blood. cccDNA cannot be measured in serum, and few surrogate markers have been proposed. Persistent cccDNA has been associated with various clinical events, including viral reactivation induced by immunosuppressive therapies, HBV recurrence after liver transplantation and hepatocellular carcinoma (HCC). cccDNA remains the main target to achieve a cure of HBV infection, thus extensive efforts are being made to develop new antiviral concepts to degrade or silence cccDNA.
Related Concept Videos
Hepatitis
Viruses with RNA Genomes
Size and Structure of Viral Genomes
DNA Bacteriophages
Retrovirus Life Cycles
Retroviruses

